Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFE3CD)

• Drug Name: AZD-9935 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Terminated	[1]

• Cross-matching ID: TTD Drug ID: DMFE3CD

Molecule-Related Drug Atlas

Drug(s) Targeting Vascular endothelial growth factor receptor (VEGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Intedanib	DMSTA36	Colorectal cancer	2B91.Z	Approved	[3]
Sulfatinib	DMPOTM4	Neuroendocrine cancer	2B72.1	Phase 3	[4]
Fruquintinib	DMHOSCQ	Solid tumour/cancer	2A00-2F9Z	Phase 3	[4]
KH-902	DM8VO16	Diabetic macular edema	9B71.02	Phase 3	[5]
XL-820	DMMHX9K	Solid tumour/cancer	2A00-2F9Z	Phase 2	[6]
BAY-57-9352	DMVA5NS	Gastric adenocarcinoma	2B72	Phase 2	[7]
X-82	DMW1NKO	Age-related macular degeneration	9B75.0	Phase 2	[4]
Vorolanib	DMIM1U9	Non-small cell lung cancer	2C25	Phase 2	[8]
BFH-772	DMVUX1C	Psoriasis vulgaris	EA90	Phase 2	[9]
ASP-8477	DMBZQS7	Neuropathic pain	8E43.0	Phase 2	[10]

Drug(s) Targeting Epidermal growth factor receptor (EGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Hepatocellular carcinoma	2C12.02	Approved	[11]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[12]
Gefitinib	DM15F0X	Solid tumour/cancer	2A00-2F9Z	Approved	[13]
Erlotinib	DMCMBHA	Non-small-cell lung cancer	2C25.Y	Approved	[14]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[15]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[16]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[17]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[18]
Epidermal growth factor	DMVONE6	Vulnerary	ND56.Z	Approved	[16]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Epidermal growth factor receptor (EGFR)	TTGKNB4	EGFR_HUMAN	Antagonist	[2]
Vascular endothelial growth factor receptor (VEGFR)	TTVJ1D8	NOUNIPROTAC	Antagonist	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018392)
• [2] WO patent application no. 2009,0582,67, Benzomorpholine derivatives and methods of use.
• [3] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats. Diabetes Obes Metab. 2012 Jul;14(7):644-53.
• [6] National Cancer Institute Drug Dictionary (drug id 452042).
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chin J Cancer Res. 2021 Feb 28;33(1):103-114.
• [9] CA patent application no. 841416, Method of selecting therapeutic indications.
• [10] ClinicalTrials.gov (NCT02065349) A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety. U.S. National Institutes of Health.
• [11] Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
• [12] Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
• [13] Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
• [14] Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
• [15] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [16] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
• [17] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [18] Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
• [19] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).